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 █ Abstract
Objective: To explore the lived experience of youth who are prescribed antipsychotics. Methods: We conducted an 
interpretive phenomenology study of young people with recent experience of taking antipsychotics. Youth were interviewed 
and a staged approach was used for data analysis of transcriptions. We collected approximately  
13 hours of audio from 18 youth aged 13 to 26 years between January and August of 2010. Results: Ambivalence was 
significant and antipsychotic adverse effects frequently tempered benefits. Both illness and antipsychotics had significant 
impacts on physical and mental wellbeing with adverse effects on relationships and functioning in various contexts (e.g., 
school). Stigma related to both antipsychotics and illness was also prominent. Participants’ limited knowledge about their 
antipsychotics and pressure to conform within their youth culture and context affected decisions on starting, adhering 
to, and persisting with treatment. Conclusions: The lived experience of youth taking antipsychotics is complex and the 
benefits (e.g., symptom improvement) and consequences (e.g., adverse effects) associated with antipsychotics affect all 
facets of life. More research is needed to better understand youth priorities in treatment decisions and whether youth who 
demonstrate substantive gaps in their knowledge about antipsychotics are truly given the opportunity to be informed and 
engage in management decisions including whether to initiate, persist with, and discontinue treatments.
Key Words: antipsychotic agents, qualitative research, pediatrics, young adults, physician-patient relations, 
decision-making
 █ Résumé
Objectif: Explorer l’expérience vécue d’adolescents à qui on a prescrit des antipsychotiques. Méthodes: Nous avons 
mené une étude interprétative phénoménologique auprès de jeunes gens qui ont récemment fait l’expérience de prendre 
des antipsychotiques. Les jeunes ont été interviewés et une approche graduelle a servi à l’analyse des données des 
transcriptions. Nous avons recueilli environ 13 heures d’enregistrement audio auprès de 18 jeunes de 13 à 26 ans, entre 
janvier et août 2010. Résultats: L’ambivalence était significative et les effets indésirables des antipsychotiques en ont 
souvent modéré les avantages. Tant la maladie que les antipsychotiques avaient des effets significatifs sur le bien-être 
physique et mental, et des effets indésirables sur les relations et le fonctionnement dans divers contextes (p. ex., l’école). 
/ DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT
62
Murphy et al
  J Can Acad Child Adolesc Psychiatry, 24:1, Winter 2015
Introduction
Antipsychotics are a mainstay of treatment for people with serious mental illness including psychotic dis-
orders (e.g., early psychosis, schizophrenia). Prescription 
of second generation antipsychotics to people under 25 
years of age continues to increase (Alessi-Severini, Bis-
contri, Collins, Sareen, & Enns, 2012; Cooper et al., 2006; 
Harrison-Woolrych, Garcia-Quiroga, Ashton, & Herbison, 
2007; Murphy et al., 2013; Olfson, Blanco, Liu, Wang, 
& Correll, 2012; Pringsheim, Lam, & Patten, 2011; Rani, 
Murray, Byrne, & Wong, 2008; Vitiello et al., 2009; Zito 
et al., 2008) despite controversy regarding effectiveness 
and safety data (Canadian Adverse Reaction Newsletter, 
2012; Panagiotopoulos, Ronsley, Elbe, Davidson, & Smith, 
2010; Pringsheim, Lam, Ching, & Patten, 2011; Seida et 
al., 2012). Young people’s experiences of psychotropics, 
especially antipsychotics, have not been substantively ex-
plored. There is some information on their perceptions of 
effects on their bodies, behaviours, thoughts, and hopes 
(Floersch, 2003; Floersch et al., 2009; Longhofer & Flo-
ersch, 2010; Moses, 2011) but less on emotions, cognitions, 
and social functioning. A greater understanding regarding 
emotions, cognitions, social functioning, and coherence of 
youth prescribed these medications is of particular impor-
tance for clinicians, patient advocates, and policy makers 
(Friedli, 2009). In this paper, we report our findings from an 
interpretive phenomenological analysis of young people’s 
experience with antipsychotics. 
Methods
Interpretive phenomenological analysis examines the lived 
experience within a particular situation/context (Benner, 
1985; Smith, Flowers, & Larkin, 2009) and includes a 
“double hermeneutic” (Smith et al., 2009) in which the re-
searcher makes sense of the participant, who, in turn, makes 
sense of their own experience.
Sample and recruitment procedures
Recruitment was purposeful (Smith et al., 2009) and tar-
geted youth aged 11 to 25 years with a mental illness pre-
scribed at least one antipsychotic within the last two years.
Low-income youth, including those receiving public assis-
tance for income and other expenses (e.g., prescriptions), 
were originally sought based on our pharmacoepidemiolog-
ical study, (Murphy et al., 2013) but we eliminated this cri-
terion due to insufficient recruitment. The recruitment pro-
cess was informed by clinical experience and the literature 
(Ford et al., 2008; Furimsky, Cheung, Dewa, & Zipursky, 
2008; Mapstone, Elbourne, & Roberts, 2007; Morse, Bar-
rett, Mayan, Olson, & Spiers, 2002; Robinson & Trochim, 
2007; Woodall, Morgan, Sloan, & Howard, 2010). Inter-
pretive phenomenology studies often use smaller sample 
sizes (e.g., one to ten) (Smith et al., 2009) owing largely to 
a commitment to idiography and an aim to gain deep un-
derstanding of particular phenomena in particular contexts 
(Smith et al., 2009). We aimed to recruit 24 participants, 
which is more than typically needed, in consideration of 
possible cognitive issues with participants.
Compensation
All participants were paid a one-time honorarium for their 
participation.
Data collection and analysis 
Interviews were conducted by one individual using a semi-
structured interview guide (available upon request), which 
included questions such as, “what is your experience with 
antipsychotic medications?” The interviewer was equipped 
with a list of brand and generic names of psychotropics, 
including antipsychotics available on the Canadian market. 
The interviewer and the participant used this list to deter-
mine which medications they were discussing. All encoun-
ters were recorded, transcribed, and analyzed, and anony-
mized through assignment of false initials. One participant 
requested not to be recorded. Data collection occurred 
from January to August 2010 and was stopped follow-
ing 18 interviews (13 audio hours) of youth aged 13 to 26 
Les stigmates liés à la maladie et aux antipsychotiques étaient également proéminents. Les connaissances limitées des 
participants de leurs antipsychotiques et la pression de se conformer à la culture et au contexte des jeunes influaient sur 
leur décision de commencer le traitement, de l’observer et d’y persister. Conclusions: L’expérience vécue de jeunes qui 
prennent des antipsychotiques est complexe et les avantages (p. ex., l’amélioration des symptômes) et conséquences (p. 
ex., les effets indésirables) associés aux antipsychotiques affectent toutes les facettes de la vie. Il faut plus de recherche 
pour mieux comprendre les priorités des jeunes dans les décisions liées au traitement, et pour déterminer si l’on donne 
réellement aux jeunes qui démontrent des lacunes substantielles dans leurs connaissances des antipsychotiques 
l’occasion d’être informés et de prendre des décisions quant à la prise en charge, notamment commencer le traitement, 
persister et abandonner. 
Mots clés: agents antipsychotiques, recherche qualitative, pédiatrie, jeunes adultes, relations médecin-patient, prise de 
décision
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Table 1. Interpretive phenomenological analysis process*  
(Diekelmann, Allen, & Tanner, 1989; J. A. Smith et al., 2009; J. A. Smith & Osborn, 2008; Van Manen, 1989)
Activities Purpose
Stage one Transcripts were read individually as whole. To gain a complete picture of the data.
To reflect on expressing text meaning with one or more 
“sententious phrases” (Van Manen, 1989).
Stage two Summarized the transcripts and identified 
themes.
Text quotes were provided within themes to 
demonstrate support. 
The themes were used to serve as experiential structures of the 
phenomenon (Van Manen, 1989).
Themes and interpretations served as main discussion at 
meetings as we worked to achieve consensus within themes.
To enable the team to examine meaning for participants having 
their experiences in their specific context (Smith et al., 2009).
Stage three Continued with independent analysis of 
transcripts. 
To individually compare interpretations of the themes with 
supporting text.
Stage four Sought to examine relational themes present in 
all transcripts. 
To enable moving from the particular to the shared (Smith et al., 
2009; Streubert & Carpenter, 2011) across multiple experiences.
To capture phrases that embodied the main thrust of the meaning 
of the themes (Van Manen, 1989).
*Conducted by ALM, DMG, and JH
years because of the richness of the data collected. Two 26 
year-olds participated as current antipsychotic experience 
included their 25th year. Two youths taking antidepressants 
only were inadvertently interviewed and excluded. We fol-
lowed a staged iterative and inductive analysis approach 
(Table 1). Participants were sent findings and themes for re-
view and comment for member-checking. Participants were 
also contacted, if they consented, for community knowl-
edge translation (KT) sessions regarding the study findings. 
The KT session was used for feedback, member-checking, 
and data triangulation (Streubert & Carpenter, 2011). Itera-
tive analyses and participant opportunity for review of find-
ings served as multiple lenses for establishing credibility, 
dependability, and validity (Creswell & Miller, 2000; Kreft-
ing, 1991).
Ethical approvals
Ethics approval was obtained from the research ethics 
boards (REB) of Capital District Health Authority and the 
IWK Health Centre. Both of these REBs have reciprocal 
ethical agreements with Dalhousie University’s REB.
Results
The youth experience of antipsychotics was infrequent-
ly one of monotherapy, past or current, and many youth 
had exposure to several classes of psychotropics (Table 
2). Similarly, the range of diagnoses as youth understood 
and described them included many symptoms and termi-
nology from a variety of conditions. We depict the youth 
antipsychotic experience with the metaphor “double-edged 
saw” (Figure 1), which represents major components of 
experience including significant ambivalence, desires for 
alternatives, support gaps, and stigma.
Ambivalence 
We identified themes related to desires for alternatives, sup-
port gaps, and stigma, which all contributed to ambivalence 
and decisional conflict. This ambivalence and decisional 
balancing activities of youth significantly affected whether 
they would start, continue with, or stop antipsychotics. Per-
ceived benefits were often described tentatively and juxta-
posed with adverse consequences or as tempering of symp-
toms (e.g., “level out”, “calm”, “smoothing out”, “balance”, 
“mellow”). Adverse effects impacted mental functioning 
and sense of self (e.g., “muted”, “below par”, “grey”, “zom-
bie”) as often as they were described in causing physical 
symptoms (e.g., weight gain, high blood sugar, shaking). 
These effects were often used in examples to describe daily 
situations that changed with medications such as when in-
teracting with peer groups. Strategies to overcome these ef-
fects included altering doses, stopping their medications, or 
using illicit substances. Stigma was also prominent in the 
discussions and threaded through other themes including 
ambivalence.
Elliot described accepting antipsychotics and adverse ef-
fects in light of the benefits gained:
“Respondent (R):…it was like the lesser of two 
evils....You can be scared and paranoid or you can 
have no saliva. I was going to take the no saliva 
but...it was trial and error…I’m glad I got to the 
stage…where I actually feel like they are working.”
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Luc similarly described accepting antipsychotics following 
an evolution in his experience:
“R:…and I went off my pills …By choice…Because 
I had an issue with taking them. I don’t mind taking 
them now but I had an issue...Interviewer (I):...
What was the issue? R:…like energy levels, the way 
it made me feel. It was almost as if taking the pill 
was causing depression.…it took me time to adjust 
knowing that I need to take them, knowing that 
it’s important.…I feel better now that I’ve kind of 
agreed to take my medication.”
Graham accepted treatment despite changes and trade-offs 
with symptom management:
“R: It’s good because it definitely muted any kind 
of weirdness…but it almost like kept you at a below 
par level. And when I say par... you can never like 
experience the highs anymore. It was just like grey.”
For Chloe, the acceptance of treatment included becoming 
part of a different peer group:
“R:...I have a different type of friends now…
Because after I got sick, I felt like I wasn’t the 
same person.…I couldn’t be myself around other 
people…I was so empty and I was tired and drugged 
out and numbed out...I can remember feeling shitty 
about myself because I felt like a zombie. I didn’t 
feel like myself. I had no concentration.”
She also reported using illicit drugs to manage antipsychot-
ic effects:
“R:...I battled with drug usage…when you’re 
on antipsychotics...they don’t make you feel like 
yourself. And even though you may adjust to them, 
meaning forget how you used to feel, you still crave 
that feeling of chattiness and just being more like 
yourself. And that is why I used to use drugs.”
Table 2. Youth participant demographics and self-reported current and past medications and illness 
descriptors
Youth Age
Self-reported illness descriptors transcribed 
as verbally reported 
Self-reported medication(s) current and past, 
transcribed as verbally reported
1. Tiffany (F) 19 Bipolar, depressed, mood disorder, anxiety, 
panic attacks 
quetiapine, Strattera, Adderall  
2. Kelly (F) 26 Psychosis, Psychosis NOS, sleep disorder  olanzapine, lorazepam, risperidone, citalopram, 
trazodone   
3. Billy (M) 25 Psychosis risperidone, olanzapine, ziprasidone, citalopram
4. Elliot (M) 24 Depression, paranoid, bipolar schizophrenia, 
bipolar, schizo-affective, schizophrenia with 
bipolar 
Paxil, lithium, “a lot of different antipsychotics” 
5. Pheobe (F) 18 OCD, anxiety quetiapine, Cipralex, clonazepam
6. Sara (F) 21 Schizophrenic, bipolar quetiapine, lorazepam, Risperidal, Celexa, Effexor  
7. Luc (M) 24 Psychosis risperidone
8. Graham (M) 17 Paranoia quetiapine 
9. Craig (M) 26 ADHD, bipolar schizophrenic divalproex, olanzapine 
10. Chloe (F) 23 Drug-induced psychosis, paranoid 
schizophrenia, ADHD, anxiety
Cipralex, Wellbutrin, clonazepam, risperidone
11. Jenny (F) 25 Anxiety, depression, bipolar, manic lithium, olanzapine, citalopram, Cipralex, citalopram, 
Wellbutrin, zopiclone 
12. Meagan (F) 21 Borderline personality disorder quetiapine, Zoloft, risperidone, Prozac, Paxil, 
lorazepam, clonazepam, diazepam, lorazepam
13. Beth (F) 22 Bipolar, psychosis  lithium, risperidone, ziprasidone, Cipralex, Epival
14. Gordon (M) 20 ADHD, ADD, seizure disorder, autism risperidone, Dexedrine, Ritalin, Wellbutrin
15. Steve (M) 13 ADHD, anger problem, violent behaviour Biphentin, risperidone 
16. Brandon (M) 17 Suicidal, dysthymia Seroquel 
17. Kent (M)  
(Not recorded)
19 Paranoia, hearing voices olanzapine, risperidone, clozapine, “an 
antidepressant” 
18. Tim (M) 16 Blood pressure, psychotic risperidone, lorazepam, olanzapine, ziprasidone
M = male, F= female
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Desires for alternatives
Many questioned the utility of antipsychotics with a desire 
for overcoming illness without medications through their 
own strengths (i.e., “beat” the illness “myself”), or using 
other alternatives such as “holistic”, “natural”, or “herbal” 
remedies.
Graham:
“R:…they definitely are a good thing but I don’t 
really want to use them as a crutch.…I just want to 
get over it. Which is good.”
Kelly and Sara shared views regarding herbals:
Kelly: “R:...there’s got to be other ways. There’s 
got to be like holistic things...like healthy things I 
can do to prevent my mind from going nuts....I know 
they can help like when you really need them. It’s 
just the doctors are there to recognize like when 
you really need them.…I mean people I meet and 
are taking medication, I never suggest...“Oh, stop 
taking them. Those are terrible.”...There has to be 
more like holistic, I don’t know, therapy.”
Sara: 
“R:...If I have a problem, I’d rather beat it myself 
than breaking down and letting something else take 
care of it.…I think there’s better ways to go about 
getting through that and stuff. I think they should 
be really looking at herbal remedies more so than 
that. There’s more healthier ways about it....herbal 
remedies.”
Pheobe justified antipsychotic use based on severity:
“R: I think that they should be used not as a last 
Figure 1. Youth antipsychotic experience as a double-edged saw
Youth participants’ experiences with antipsychotics, reflecting the ambivalence, tension and vacillating nature of the relationship 
between youth and their medicine. Youth ambivalence and conflict with treatment co-existed with a desire for alternative therapies 
represented by the saw teeth and the physical use of the saw (i.e., push and pull). There were significant gaps in knowledge, access to 
adequate information, and personal and health care service supports experienced by youth in our study and are represented by the saw 
teeth. These gaps were often acknowledged and seen as significant for youth but they had limited ability and understanding about how 
to bridge the gaps. Ultimately, this led to placement of the prescriber and youth treatment decisions on opposing sides with a disconnect 
between the groups. The metaphor serves to depict the language used by youth in the journey of starting and persisting with treatments 
in a passive manner with changes being done to them as opposed to an active participant in decision-making. They discussed being 
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resort because I don’t think anybody should have 
to go through hell to get them or have to be really, 
really, really bad that they risk not being able to get 
better.…they shouldn’t be prescribed like candy...or 
as frequently as SSRIs are because they are a really 
heavy drug....if there’s more gain than risk, and the 
person is willing to try it, that they should be able 
to go on them....they should definitely be supervised 
while they are on it, and be able to ask questions...
And…have therapy with it. Because generally when 
you are on an antipsychotic, it’s for something 
quite severe. Or hopefully it’s for something quite 
severe....They should definitely have follow-up care 
to help them, not just help the dopamine.”
Gaps in support
Support gaps were evident in many areas (e.g., knowledge, 
peers, family, health services, goal and priority setting) that 
would be considered necessary to make informed treatment 
choices and recover from illness. Many participants were 
unable to contextualize or quantify risks or benefits of treat-
ments. For some, the risks of treatments led to gaps in peer 
supports and loss of relationships, stigma, and future con-
cern for disclosures.
Chloe described a lack of support from a previous partner 
and anticipated the future with a “bomb” (i.e., awesome or 
great) partner:
“R:…He was like “oh, at least I don’t take meds 
once a month”. I was like, “who cares? At least 
I know they are good for me”.…You know, I’m 
worried that I might meet this bomb guy and that 
I might have to hide it from him, and then all of a 
sudden he finds this purse full of pills and he’s like, 
“What the hell?”...“Wow, this girl is a pharmacy on 
wheels.” And it does create…worry that somebody 
will judge me and think, “oh, she’s crazy”. Even 
though I know I’m not.”
She also discussed her lack of involvement in decisions 
about her care while experiencing loss of family supports 
after hospitalization:
“I:…and how you were involved in making decisions 
about your care. R:…I think it was mostly enforced 
on me. I was told I had to take this medication.…
when I was discharged from the hospital,…at the 
last minute, my dad says, “No, you can’t stay with 
me.” So like within 3 days before I had to leave the 
hospital, I had to make a quick decision in the frail 
state that I was in…”
Jenny described a supportive network with family and 
friends. She also had praise for her doctors yet she con-
veys in her story a patchwork of accessibility challenges 
and concern from her mother regarding accessibility of a 
care provider: 
“R:...My family doctor, I could see probably at the 
drop of a hat. I mean she is a very busy woman 
but I have a few connections. My psychiatrist, she’s 
always said, “If you ever need me, you have to call 
me.” And I have called just about blood work or 
different things. But she’s a very, very busy woman, 
and she travels I think 18 weeks out of the year 
for conferences and vacation. So my mom, when 
I came out of the hospital the second time, was 
a little scared or was hesitant about going back 
knowing that that was my only doctor to fall onto. 
But like Dr. [name] from [hospital] said, “if there’s 
anything ever you need…”. I have his information.”
She also described serendipitous discovery of adverse 
effects despite reporting good relationships with her 
physicians:
“I: And is menstruation stopping a side effect? R: 
Yes. I: And did they tell you about that? R: No one 
told me. I looked that up under the side effects. 
I: What were you told, do you remember? R: For 
side effects? Nothing. I: Nobody told you any side 
effects for lithium or olanzapine? R: No, not until 
I started seeing...my psychiatrist, I would tell her 
my side effects and she’d say, “Yes.” Like she’d 
nod and say like, “Yes, that is normal.” So she’s 
never given me any reason to believe that these side 
effects are something...I: Extreme. R: Yes.”
Youth like Luc used various information sources includ-
ing physicians, peer groups, the Internet, and the pharmacy 
“print-off”:
“R: I get my information from my psychiatrist, and 
I got the print-off from...Well, you know when you 
see prescriptions anyway, the list of side effects 
that you may or may not get. And it’s like umpteen 
million....with Risperdal...it can cause permanent 
diabetes. And my blood sugar levels are a little 
bit high since I’ve been taking the pill…inability 
to conceive children. That’s also a possibility. And 
I’m worried about that one.…I get this list of side 
effects, and I’m like, “Ah, what am I going to get?”
Another important gap in knowledge for many youth was 
long-term treatment expectations.
Beth:
“I:…what kind of conversations are you having 
about the long term plan for you [with psychiatrist]? 
R: I don’t think we’ve had any long-term plans. He’s 
asked me like my education goals...But nothing 
beyond that...I: Have you been told anything about 
how long you might be on the antipsychotic? R: Oh, 
I just figured it was indefinitely.…I: What do you 
know about the side effects?…R: Well, I know it 
affects my heart because it changes the rhythm. But 
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I actually don’t know all there is to know about it. I 
just know what’s on the medication info, whatever 
comes with the medication.”
Support gaps and stigma were evident in the school system. 
Steve had negligible involvement in decision-making and 
the school personnel had influence with treatments:
“R:…my EA [educational assistant] said I should 
be put on another kind of medication. Because she 
used to work as a [health care professional].…I: …
your EA was talking to you and was wondering if 
maybe something else might be better? R: Yes. I: 
And so what happened then? R: I went to the doctor 
and got on another kind of pill...I: The risperidone…
your EA is talking to you about changing pills….
So when he [the doctor] was suggesting another 
medicine, did he talk to you about what it might be 
like to take it?…What did he tell you?...R: Actually, 
he mostly talked to my mother. I:…Were you in the 
room? R: Yes. I: But you didn’t feel like he was 
talking to you? R: Not really. I: Did you feel like 
you could ask questions? R: No.”
For Gordon, medications were stigmatizing and his experi-
ence demonstrated a lack of support from school person-
nel. Changes in his behaviour were attributed to a lack of 
medications:
“R:…they’d be like, “Oh, you’re acting weird now. 
Did you take your medicine this morning?”.
Tim also discussed stigma and lack of support from peers 
and his father while managing potentially severe side ef-
fects in front of his friends:
“I: Do they [the school] talk to you about it at 
all? R: They ask me if I need them sometimes.…
The teachers, the kids there are okay...Sometimes 
they’ll say names to me…I’m not supposed to react 
to it. I:...Do you talk about your medicine with your 
friends…? R: Well, when my eyes roll up, I have 
to explain something to them or else they’ll just 
think I’m weird...I said it was from…my other pills. 
I don’t think I should have did that…they kept on 
asking me why I was looking up, and why I took 
that orange pill when they weren’t looking. I:…you 
said maybe you shouldn’t have [told them]. Why? 
R: Because they know and they’re not supposed to. 
That is what my dad said.”
Discussion
Youth in our study expressed significant ambivalence about 
antipsychotics, fuelled by a lack of information about both 
their treatment and illness, and stigma that prevented con-
formity within their culture and context (e.g., school). Our 
findings raise questions around informed consent including 
when and how frequently these discussions occurred tak-
ing into account cognitive abilities, illness severity, and 
capacity. The process of self-determination (Cook & Joni-
kas, 2002) and navigating decisional junctures, (i.e., seek-
ing help, accepting treatment, continuing treatment, and 
deciding to stop medication) (Malpass et al., 2009), in our 
participants’ experiences appeared inadequately supported 
by clinicians and others (e.g., family, peers, Internet). The 
traditional or paternalistic decision-making model (Charles, 
Gafni, & Whelan, 1999) appeared to predominate in the 
participants’ experiences, which supports findings that in 
psychiatry there is variability in application of decision-
making approaches with paternalistic (or traditional) de-
cision-making models reported as a preferred method by 
prescribers (Hamann et al., 2009; Hamann et al., 2012; Ha-
mann, Leucht, & Kissling, 2003). As a result, youth relied 
on personal experience and incomplete information from 
sources that ranged in credibility.
Our findings highlight the importance of national and inter-
national initiatives that encourage patient-centered care and 
involvement in treatment decision-making (Chow, Basky, 
Teare, & Health Quality Council, 2009; National Health 
and Medical Research Council, 2004). Unfortunately, to 
our knowledge shared decision-making models have not 
been applied to children or young people taking psychotro-
pics, especially antipsychotics (Moses, 2011).
Limitations 
We did not specifically request information or have access 
to medical records to verify diagnoses or specific names of 
antipsychotics. Participants reported both a wide range of 
medications including antipsychotics, as well as diagnoses 
and/or symptoms. This may have affected their ability to 
accurately identify all the medications they were prescribed 
and if experiences were specific to antipsychotics. It is also 
possible that recall and responses may have been affected 
by illness, side effects from treatments, or the youth’s readi-
ness and willingness to engage in treatment discussions. 
Although the sample size is suitable for an interpretive phe-
nomenological study with rich description, the experiences 
and our interpretation are only of the youth that were inter-
viewed. We cannot claim that our interpretation of the data 
is the only possible interpretation.
Recommendations for clinical 
practice and research:
• Clinicians and patients alike need to know that 
antipsychotic-related decision-making is to be a 
fluid, longitudinal process involving clinicians, 
patients, and (when appropriate) their families and/
or support people, recognizing that factors influencing 
decisions are dynamic and can change over time. 
Setting and re-visiting treatment goals and evaluating 
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patient progress and information needs are to be 
routinized in practice settings through efficient and 
effective strategies and techniques. Examples include: 
environmental restructuring with electronic health 
record-based prompts that can assist prescribers in 
asking youth about progress and updating goals for 
treatment; and the use of resources such as Med Ed 
(Murphy, Gardner, Kutcher, Davidson, & Manion, 
2010), that enable youth to actively engage in seeking 
medication information towards informed decision-
making. Implementing these resources in practice 
may require support (e.g., personnel, technological, or 
financial) that extends beyond the means of individual 
clinicians.
• Clinicians should be cognizant that antipsychotic-
related decisions will occur at times when youth are 
experiencing challenges with one or more of various 
domains of brain functioning including cognition, 
perception, emotion, behaviour, somatic, and 
signaling, which may ultimately impact capabilities 
and motivations to make decisions. Information 
sharing therefore needs to be included at all patient 
care visits with modification of the complexity of the 
information to meet the patient’s capacity and level 
of engagement. When several health care providers 
or teams are involved, such as during transitions of 
care (e.g., inpatient to outpatient, pediatric to adult), 
clear communication processes among providers and 
patients and/or families need to be in place.
• Research is needed to examine ways to improve shared 
or informed decision-making for youth of various ages 
taking antipsychotics. This will require exploration 
of strategies and techniques for changing behaviours 
of clinicians, patients, and families (when applicable) 
in clinical encounters. Although there are a host of 
potential tools and techniques available (e.g., decision 
aids, goal setting, action planning, etc.,) we have very 
little information on the mechanisms and techniques 
for changing behaviour that are the most appropriate 
and efficient. One technique that shows promise is 
motivational interviewing (Hamrin & McGuinness, 
2013), which is an approach that has been applied to 
antipsychotics (Kisely, Ligate, Roy, & Lavery, 2012) 
yet more information is needed to fully appreciate the 
efficacy and feasibility of these kinds of interventions 
in daily practice.
Conclusions 
The lived experience for youth taking antipsychotics is 
complex and the benefits and consequences associated with 
antipsychotics affect all facets of life. Significant ambiva-
lence exists for youth who are prescribed antipsychotics. 
More research is needed to better understand whether youth 
are truly informed in their choices to initiate, persist with, 
and discontinue antipsychotics given complexities (e.g., 
stigma, developmental stage, potential for multiple medica-
tion usage) and the significant gaps in their knowledge.
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